Compare Johnson & Johnson (JNJ) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Philip Morris International Inc. — how do they compare? Johnson & Johnson trades at $261.26 (market cap $626.09B), while Philip Morris International Inc. trades at $185.99 (market cap $290.24B). The key difference: Johnson & Johnson is far larger — about 2.2× Philip Morris International Inc.'s market cap, and Philip Morris International Inc. pays the higher dividend (3.16%). Which is the better fit depends on your goals.
| JNJ | PM | |
|---|---|---|
Market Cap | $626.09B | $290.24B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Staples |
52-Week High | $267.24 | $200.17 |
52-Week Low | $172.78 | $144.33 |
Enterprise Value | $654.37B | $333.36B |
Dividend Yield | 2.06% | 3.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.81, up 0.99% on the day and near its 52-week high. The stock exhibits bullish technical signals with strong moving average support, while fundamentals show robust profitability with a net income margin of 21.48% and consistent dividend growth. Recent earnings have mostly beaten expectations, and the company maintains a solid balance sheet with $24.52 billion in cash.
The outlook for JNJ remains positive, supported by analyst consensus and a price target of $284.50. Key opportunities include its defensive healthcare positioning and pipeline strength, though risks involve patent expirations and legal headwinds. The stock offers a stable investment with growth potential in a volatile market.
Philip Morris International (PM) trades at $186.00, down 1.88% on the day, with a neutral technical signal. The stock shows strong profitability with a 25.56% net income margin and has beaten earnings estimates in two of the last three quarters. Recent news highlights a $500 million impairment charge and a lowered profit forecast due to cost pressures, though the IQOS brand was recognized as a top global brand. Analyst consensus remains bullish with a $211.17 price target.
The outlook is mixed; strong cash flow and brand strength support long-term value, but near-term headwinds from cost inflation and illicit market growth pose risks. The current valuation at a P/E of 25.57 appears fair given earnings resilience, making PM a hold for investors tolerant of sector-specific volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
